Benzinga · Feb 27, 2026
CG
NASDAQ · CGON
CG Oncology, Inc. Common stock
Healthcare · Biotechnology
$79.01
Up+$0.59 (+0.75%)
Updated Aug 28, 2026, 9:00 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.12B
- P/E ratio
- -29.65
- Dividend yield
- 0.00%
- 52-week range
- $25.25 – $80.97
- Volume
- 328.93K
- Avg. volume
- 990.79K
Price performance
CGON price history
1M range · 21 trading sessions · Daily adjusted prices
CGON closed at $79.01 after 21 trading sessions, up 8.19% for the selected period.
- Last close
- $79.01
- Period change
- +8.19%
- Period low
- $69.15
- Period high
- $80.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $78.01 | $79.40 | $77.63 | $79.01 | 328.93K |
| Aug 26, 2026 | $78.29 | $78.94 | $76.87 | $78.42 | 507.81K |
| Aug 25, 2026 | $79.00 | $80.07 | $78.10 | $78.95 | 736.17K |
| Aug 24, 2026 | $79.44 | $79.89 | $77.51 | $78.23 | 1.16M |
| Aug 21, 2026 | $78.69 | $79.89 | $77.38 | $79.81 | 701.89K |
| Aug 20, 2026 | $79.50 | $79.7075 | $77.17 | $77.61 | 668.03K |
| Aug 19, 2026 | $77.80 | $80.97 | $77.00 | $80.68 | 845.88K |
| Aug 18, 2026 | $75.83 | $77.50 | $75.31 | $76.29 | 562.5K |
| Aug 17, 2026 | $73.87 | $77.42 | $73.87 | $77.11 | 958.38K |
| Aug 14, 2026 | $74.54 | $75.66 | $73.50 | $75.03 | 596.28K |
| Aug 13, 2026 | $77.25 | $77.48 | $74.58 | $74.71 | 748.89K |
| Aug 12, 2026 | $77.50 | $79.39 | $76.2101 | $76.99 | 766.13K |
| Aug 11, 2026 | $76.68 | $77.49 | $75.34 | $77.03 | 809.61K |
| Aug 10, 2026 | $74.64 | $76.59 | $74.57 | $76.56 | 811.3K |
| Aug 7, 2026 | $74.97 | $76.20 | $73.51 | $75.10 | 611.59K |
| Aug 6, 2026 | $71.85 | $76.50 | $71.85 | $74.85 | 936.06K |
| Aug 5, 2026 | $71.47 | $73.815 | $71.26 | $72.42 | 922.87K |
| Aug 4, 2026 | $69.62 | $72.64 | $69.62 | $71.40 | 883.31K |
| Aug 3, 2026 | $71.29 | $71.29 | $68.08 | $69.15 | 625.95K |
| Jul 31, 2026 | $72.94 | $72.94 | $69.602 | $71.19 | 561K |
| Jul 30, 2026 | $69.22 | $73.32 | $67.12 | $73.03 | 536.46K |
Latest CGON news
The latest Smart Investors Daily articles mentioning CGON.
Stock researchCompany · Overview
CGON research
Overview
Company profile and research snapshot.
Company profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $69.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| May 19, 2026 | Wolfe Research | Peer Perform | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 27, 2026
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
Benzinga · Feb 27, 2026
CG Oncology Q4 Earnings Report: What Investors Need to Know
Benzinga · Feb 27, 2026
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 10.87 percent decrease over losses of $(0.46) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
